[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ellis et al., 2010 - Google Patents

Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease

Ellis et al., 2010

View PDF @Full View
Document ID
15029382987386943816
Author
Ellis C
Rutledge J
Underwood M
Publication year
Publication venue
Gut microbes

External Links

Snippet

Necrotizing enterocolitis (NEC) is the most common intestinal emergency among premature infants. Risk factors in premature infants include immature intestinal immunity and an intestinal microbiota dominated by hospital-acquired bacteria. Some probiotics have been …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Similar Documents

Publication Publication Date Title
Ramirez et al. Antibiotics as major disruptors of gut microbiota
Oka et al. Microbial-based and microbial-targeted therapies for inflammatory bowel diseases
Kong et al. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet
Álvarez-Mercado et al. Microbial population changes and their relationship with human health and disease
Gerritsen et al. Intestinal microbiota in human health and disease: the impact of probiotics
Brahe et al. Can we prevent obesity-related metabolic diseases by dietary modulation of the gut microbiota?
Wang et al. Core gut bacteria analysis of healthy mice
Haque et al. The ecological community of commensal, symbiotic, and pathogenic gastrointestinal microorganisms–an appraisal
Sigall-Boneh et al. Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by D-ECCO working group [dietitians of ECCO]
Kim et al. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation
Tamanai-Shacoori et al. Roseburia spp.: a marker of health?
Fujimura et al. Role of the gut microbiota in defining human health
Bonfrate et al. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options
Cresci et al. Gut microbiome: what we do and don't know
Celiberto et al. Probiotics: The scientific evidence in the context of inflammatory bowel disease
Reid et al. New scientific paradigms for probiotics and prebiotics
Prakash et al. Gut microbiota: next frontier in understanding human health and development of biotherapeutics
O′ Toole et al. Probiotic bacteria influence the composition and function of the intestinal microbiota
Nagata et al. Effect of the continuous intake of probiotic-fermented milk containing Lactobacillus casei strain Shirota on fever in a mass outbreak of norovirus gastroenteritis and the faecal microflora in a health service facility for the aged
Tuohy et al. Diet-microbe interactions in the gut: Effects on human health and disease
Berg et al. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?
Caffarelli et al. Use of probiotics in pediatric infectious diseases
Maity et al. Impact of a gastrointestinal stable probiotic supplement Bacillus coagulans LBSC on human gut microbiome modulation
Louis-Jean et al. Nutritionally attenuating the human gut microbiome to prevent and manage metabolic syndrome
Ellis et al. Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease